hotspot -WSS

hotspot

author：comprehensive 2025-09-30 17:03:54 - browse：453

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Ending health disparities requires full federal government, panel says

WSS

Stoke drug shows lower activity against childhood epilepsy

Stoke drug shows lower activity against childhood epilepsy

New air purifier tech could be key to improving indoor air quality

DIEP, the 'gold standard' of breast reconstruction, is under threat

DIEP, the 'gold standard' of breast reconstruction, is under threat

Walensky prepares to leave CDC — and Congress — behind

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

The high cost of giving birth even with insurance

Medicare details structure of new drug price negotiation program

At least 13 dead in Texas as scorching temps continue

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hollywood unions extend contract negotiations for actors

Peter Hotez and the public health issue of online harassment

VC firm RA Capital starts a new synthetic biology incubator

Medicare proposal to cover medical devices draws a mixed reaction

Drug repurposing or repositioning? The language matters

entertainment

Activists slam private health insurers over coverage restrictions

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Sports medicine is finally prioritizing gender equality

Medicare proposal to cover medical devices draws a mixed reaction

Apple is now the first public company to be valued at $3 trillion

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

explore

leisure time

leisure time

hotspot